PharVision Advisers’s Halliburton HAL Stock Holding History

PharVision Advisers’s Portfolio HAL Stock Details HAL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,980	Closed	-$202K	–	341
2025 Q1	$202K	Buy	+7,980	New	+$210K	0.28%	199

Other funds holding HAL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's HAL Position: Q2 2025 in Review

PharVision Advisers sold out of Halliburton (HAL) in Q2 2025, closing a stake of 7,980 shares — an estimated $202K sold.

PharVision Advisers first reported a position in HAL in Q1 2025 and held it in 1 quarter. The position peaked at $202K in Q1 2025. 900 funds tracked by Wall St. Rank hold HAL as of Q2 2025.

PharVision Advisers reported no remaining Halliburton position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 7,980 Halliburton shares in Q2 2025, an estimated $202K.
PharVision Advisers first reported a position in Halliburton in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Halliburton position peaked at $202K in Q1 2025.
900 funds tracked by Wall St. Rank held Halliburton as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.